AstraZeneca taps AI for drug discovery in deal with Berg

AstraZeneca has forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting, in the latest sign of big pharma's interest in using supercomputers for drug discovery.


Please note: That all fields marked with an asterisk (*) are required.